IL17A and neoplasm: Treatment with dual ICI in combination with rm-IL-17A also decreased tumor growth (P = 0.0073 versus controls), whereas the addition of α-IL-17A strongly blocked the anti-tumor effect of dual ICI (P = 0.0130 versus dual ICI; Fig. 2a) and significantly shortened survival (Extended Data Fig. 2a).